In 2015, Texas-based ice cream darling Blue Bell Creameries was forced to implement a nationwide recall of its products after a mass Listeria outbreak. Indeed, the fallout was severe: a hefty DOJ fine of $19.35 million, the disposal of over 8 million gallons of product, and layoffs of approximately 37% of Blue Bell's workforce. 

What has since followed was not merely a food safety crisis but a legal saga spanning federal criminal proceedings, an ongoing Delaware shareholder derivative lawsuit trial, and a protracted insurance coverage dispute over the duty to defend and indemnify Blue Bell's top brass in the shareholder derivative litigation. Blue Bell's effort to obtain defense from its commercial general liability carriers—rather than dedicated D&O coverage—was decisively rejected by the Fifth Circuit. The scoop? CGL policies do not exist to shield executives from the consequences of failed corporate governance and inadequate insurance policy coverage.

The Insurance Coverage Dispute: CGL vs. D&O Policies

While CGL policies are designed to indemnify policyholders against third-party claims for bodily injury, property damage, and the ever-litigated "occurrences," D&O insurance is specifically designed to protect corporate directors and officers from being held liable in their management of corporate affairs. D&O insurance usually ends up covering the corporate entity, legal fees, and settlements. Virtually all public companies purchase D&O insurance because of heightened regulatory scrutiny and exposure to securities claims, and many private companies do as well—though some opt out entirely (as seen in the Blue Bell litigation) or purchase policies with higher exclusions or lower limits. 

Blue Bell's Coverage Maneuver and the Insurers' Response

Insurers had issued CGL policies to Blue Bell between 2009 and 2016. However, several years into the Delaware shareholder litigation, Blue Bell made an interesting move: in April 2021, it asserted for the first time that its CGL carriers owed it defense coverage for the derivative suit. The carriers ostensibly rejected this position and preemptively filed a declaratory judgment action seeking a determination that no coverage existed under their CGL policies. 

Blue Bell's rationale: the underlying "occurrence"—a Listeria outbreak caused physical harm to consumers—sounded in bodily injury, a core CGL policy trigger. Blue Bell also argued that its directors and officers were sued for decisions made while acting in their fiduciary capacities (a la Caremark), and that the Listeria events fell within the CGL's bodily injury coverage. However, the Fifth Circuit decisively affirmed the denial of coverage, disregarding the bodily injury theory as inapplicable because the shareholder litigation sought damages to cover the economic losses caused by Blue Bell's directors' and officers' breach of fiduciary duties, not bodily injury damages from the Listeria outbreak itself.

The D&O Coverage Gap

The Blue Bell litigation exposes a vulnerability among privately held companies. As discussed earlier, unlike their public counterparts, private companies are not compelled by securities regulations to maintain D&O insurance. But inadequate coverage, or worse, no coverage at all, exposes private companies to risky litigation exposure. 

However, even where D&O coverage exists, coverage is not unlimited. Once coverage limits are exhausted, directors and officers might still be exposed. This risk is compounded when, as seen with Blue Bell, the company lacks the policy protection that might have otherwise funded an early settlement. Indeed, D&O insurers tend to prefer funding defense costs and settlements rather than litigating coverage, because the alternative of a trial on the merits creates unpredictable exposure for the insurer as well as the insured.

The Blue Bell Trial: A Stress Test for Caremark

In the landmark Delaware Court of Chancery case In re Caremark International Inc. Derivative Litigation, the court articulated the foundational oversight duty for the board of directors to adequately implement and oversee information and reporting systems to ensure that the corporation operates lawfully. 

Breach of the oversight duty requires a showing of either: (1) failure to implement any reporting or information system, or (2) a conscious failure to monitor or oversee systems or controls despite red flags.

Historically, Caremark claims have been rare due to the difficulty of the scienter requirement that a plaintiff must show a director's intentional dereliction or conscious disregard of fiduciary duties. Nonetheless, Delaware courts have historically been reluctant to second-guess good-faith business judgments, and settlements were common before trial. Indeed, even the Boeing derivative litigation involving a similar Caremark breach of duty settled for $237.5 million in 2021. 

However, the ongoing Blue Bell trial is significant precisely because it did not settle. The absence of D&O insurance may have removed the practical incentive that causes similarly situated defendants to settle. As a result, the Delaware Chancery Court is forced to grapple with factual questions that almost never reach trial.

Conclusion

Whatever the outcome, the Blue Bell story reinforces the importance of having robust insurance. While Blue Bell's CGL theory was legally crafty, at the end of the day, it likely would have had earlier settlement opportunities if it had obtained adequate D&O insurance. The lessons of Blue Bell are not just limited to bad ice cream. Any company—public or private—faces analogous risks when it underestimates the potential gaps in its insurance coverage.